Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Li_Ning
|
| gptkbp:collaboratedWith |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:developedBy |
monoclonal antibodies
biological drugs |
| gptkbp:engagedIn |
clinical trials
drug discovery biopharmaceutical research |
| gptkbp:focusesOn |
immuno-oncology
innovative drugs |
| gptkbp:foundedIn |
2012
|
| gptkbp:headquartersLocation |
gptkb:Shanghai,_China
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shanghai Junshi Biosciences
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:listedOn |
gptkb:Hong_Kong_Stock_Exchange
|
| gptkbp:notableProduct |
gptkb:toripalimab
|
| gptkbp:numberOfEmployees |
over 2000
|
| gptkbp:researchCentersIn |
gptkb:China
gptkb:United_States |
| gptkbp:stockSymbol |
gptkb:1877.HK
|
| gptkbp:toripalimabIs |
PD-1 inhibitor
|
| gptkbp:website |
https://www.junshipharma.com
|
| gptkbp:bfsParent |
gptkb:Zhangjiang
|
| gptkbp:bfsLayer |
6
|